0001493152-23-042663.txt : 20231124 0001493152-23-042663.hdr.sgml : 20231124 20231124160008 ACCESSION NUMBER: 0001493152-23-042663 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231120 FILED AS OF DATE: 20231124 DATE AS OF CHANGE: 20231124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Finley John David CENTRAL INDEX KEY: 0001851034 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33672 FILM NUMBER: 231436700 MAIL ADDRESS: STREET 1: C/O SENECA BIOPHARMA, INC. STREET 2: 20271 GOLDENROD LANE CITY: GERMANTOWN STATE: MD ZIP: 20876 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PALISADE BIO, INC. CENTRAL INDEX KEY: 0001357459 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 522007292 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7750 EL CAMINO REAL, SUITE 5200 CITY: CARLSBAD STATE: CA ZIP: 92009 BUSINESS PHONE: (858) 704-4900 MAIL ADDRESS: STREET 1: 7750 EL CAMINO REAL, SUITE 5200 CITY: CARLSBAD STATE: CA ZIP: 92009 FORMER COMPANY: FORMER CONFORMED NAME: Seneca Biopharma, Inc. DATE OF NAME CHANGE: 20200127 FORMER COMPANY: FORMER CONFORMED NAME: Neuralstem, Inc. DATE OF NAME CHANGE: 20060324 4 1 ownership.xml X0508 4 2023-11-20 0 0001357459 PALISADE BIO, INC. PALI 0001851034 Finley John David 7750 EL CAMINO REAL, SUITE 2A CARLSBAD, CA 92009 1 1 0 0 CEO, CFO, Director 0 Common Stock, par value $0.01 2023-11-20 5 A 0 E 10000 0.51 A 57781 D Common Stock, par value $0.01 777 I By FCW Investments, LLC Restricted Stock Units 2023-11-21 4 A 0 38000 0.00 A Common Stock 38000 38000 D Common Stock Options 0.59 2023-11-21 4 A 0 45000 0.00 A 2033-11-21 Common Stock 45000 45000 D Shares were purchased pursuant to the Palisade Bio, Inc. 2021 Employee Stock Purchase Plan, as amended ("ESPP") for the ESPP purchase period from July 1, 2023 through November 20, 2023. In accordance with the ESPP, the shares were purchased in a transaction exempt under Rule 16b-3(c) at a price equal to 85% of the closing price of the issuer's common stock on November 20, 2023. Reporting Person is the managing member of FCW Investments LLC and has the sole investment and voting power over the securities held by this entity. The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024. N/A. Each option represents the right to purchase one share of common stock at the exercise price. The grant vests in twelve (12) equal quarterly installments over a three (3) year period from the grant date. /s/ JD Finley 2023-11-24